# A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery

> **NCT05316688** · PHASE1,PHASE2 · TERMINATED · sponsor: **University of Washington** · enrollment: 8 (actual)

## Conditions studied

- Oral Cavity Squamous Cell Carcinoma
- Stage I Lip and Oral Cavity Cancer AJCC v8
- Stage II Lip and Oral Cavity Cancer AJCC v8
- Stage III Lip and Oral Cavity Cancer AJCC v8
- Stage IVA Lip and Oral Cavity Cancer AJCC v8

## Interventions

- **PROCEDURE:** Near Infrared Imaging
- **PROCEDURE:** Therapeutic Conventional Surgery
- **DRUG:** Tozuleristide

## Key facts

- **NCT ID:** NCT05316688
- **Lead sponsor:** University of Washington
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-04-17
- **Primary completion:** 2025-09-09
- **Final completion:** 2025-09-26
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Terminated due to suboptimal delineation of fluorescence between tumor and native oral cavity mucosa.
- **Last updated:** 2026-02-25

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05316688

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05316688, "A Fluorescent Tumor Marking Agent, Tozuleristide, for Imaging Oral Cavity Squamous Cell Cancer and High-Grade Oral Cavity Dysplasia During Surgery". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT05316688. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*